{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:16:53Z","timestamp":1770743813170,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.anndiagpath.2021.151790","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T03:06:54Z","timestamp":1626404814000},"page":"151790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["B-prolymphocytic leukemia: Is it time to retire this entity?"],"prefix":"10.1016","volume":"54","author":[{"given":"Siba","family":"El Hussein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2021.151790_bb0005","series-title":"B-Cell Prolymphocytic Leukemia. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2141.1974.tb06769.x","article-title":"Prolymphocytic leukaemia","volume":"27","author":"Galton","year":"1974","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1980.tb07140.x","article-title":"Cell volume studies in B-cell leukaemia","volume":"45","author":"Costello","year":"1980","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.1979.tb03676.x","article-title":"&apos;Prolymphocytoid&apos; transformation of chronic lymphocytic leukaemia","volume":"41","author":"Enno","year":"1979","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2559.1980.tb02893.x","article-title":"The histopathology of prolymphocytic leukaemia with particular reference to the spleen: a comparison with chronic lymphocytic leukaemia","volume":"4","author":"Lampert","year":"1980","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.1986.tb07575.x","article-title":"The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. II. Patterns of evolution of &apos;prolymphocytoid&apos; transformation","volume":"64","author":"Melo","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.1986.tb05563.x","article-title":"The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group","volume":"63","author":"Melo","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0040","first-page":"339","article-title":"Chronic lymphocytic leukemia and prolymphocytic leukemia: a clinicopathological reappraisal","volume":"12","author":"Melo","year":"1987","journal-title":"Blood Cells"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0045","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2141.1984.tb06112.x","article-title":"Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia","volume":"58","author":"Pittman","year":"1984","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0050","first-page":"577","article-title":"Prolymphocytic leukaemia: surface morphology in 21 cases as seen by scanning electron microscopy and comparison with B-type CLL and CLL in &apos;prolymphocytoid&apos; transformation","volume":"57","author":"Polliack","year":"1984","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0055","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V58.2.406.406","article-title":"Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7","volume":"58","author":"Catovsky","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0060","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised","article-title":"T-Cell prolymphocytic leukemia","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0065","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/1097-0142(19811201)48:11<2447::AID-CNCR2820481118>3.0.CO;2-B","article-title":"Prolymphocytic transformation of chronic lymphocytic leukemia","volume":"48","author":"Kjeldsberg","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0070","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.leu.2404183","article-title":"Richter&apos;s and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation","volume":"20","author":"Reiniger","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/1097-0142(19860101)57:1<75::AID-CNCR2820570116>3.0.CO;2-X","article-title":"Prolymphocytic transformation of chronic lymphocytic leukemia. a report of three cases and review of the literature","volume":"57","author":"Ghani","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000204747","article-title":"Central nervous system involvement in prolymphocytic transformation of chronic lymphocytic leukemia","volume":"87","author":"Thiruvengadam","year":"1992","journal-title":"Acta Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0085","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0145-2126(86)90241-9","article-title":"Prolymphocytoid transformation of CLL: a clinical and immunological study of 22 cases","volume":"10","author":"Stark","year":"1986","journal-title":"Leuk Res"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<98::AID-AJH20>3.0.CO;2-X","article-title":"Prolymphocytic transformation in chronic lymphocytic leukemia presenting as bilateral periorbital swelling","volume":"59","author":"Gujral","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0095","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ajh.24473","article-title":"Histologic transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"91","author":"Agbay","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0100","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.V76.7.1387.1387","article-title":"Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus","volume":"76","author":"Williams","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0105","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood.V76.10.2086.2086","article-title":"Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation","volume":"76","author":"Medeiros","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0110","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1309\/PPK0-TJUK-1UAR-3194","article-title":"Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma","volume":"115","author":"Schlette","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1309\/4LTE-JHNC-C8RC-FGWL","article-title":"Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia","volume":"117","author":"Wong","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2004.04913.x","article-title":"B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia","volume":"125","author":"Ruchlemer","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0125","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.humpath.2012.01.003","article-title":"Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation","volume":"43","author":"Hoehn","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0130","first-page":"5761953","article-title":"Splenic B-cell lymphomas with diffuse cyclin D1 protein expression and increased prolymphocytic cells: a previously unrecognized diagnostic pitfall","volume":"2018","author":"Algashaamy","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.17141","volume":"193","author":"Gailllard","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0140","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood.2021011533","article-title":"Splenic marginal zone lymphoma with increased prolymphocytes","volume":"137","author":"Cai","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/10520290500305310","article-title":"Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10","volume":"47","author":"Lau","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.humpath.2018.09.021","article-title":"Prolymphocytic transformation of lymphoplasmacytic lymphoma: an extremely unusual event","volume":"90","author":"Zhang","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0155","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.leu.2404238","article-title":"IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL)","volume":"20","author":"Del Giudice","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0160","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood.V88.10.3953.bloodjournal88103953","article-title":"High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia","volume":"88","author":"Davi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0165","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0170","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0175","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2002-11-3456","article-title":"Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations","volume":"101","author":"Camacho","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0180","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","article-title":"Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma","volume":"101","author":"Walsh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0185","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1182\/blood-2008-03-142349","article-title":"Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL","volume":"111","author":"Crowther-Swanepoel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0190","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V99.4.1299","article-title":"Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course","volume":"99","author":"Algara","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2013-10-533869","article-title":"B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma","volume":"124","author":"van der Velden","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0200","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0205","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.14224","article-title":"Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia","volume":"179","author":"Gordon","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0210","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.15151","article-title":"Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme","volume":"184","author":"Eyre","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0215","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/10428194.2017.1347653","article-title":"Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations","volume":"59","author":"Damlaj","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0220","first-page":"1821","article-title":"The groupe francophone de cytogenetique H, the french innovative leukemia O: genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53","volume":"134","author":"Chapiro","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0225","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0230","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2021.151790_bb0235","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913421000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:33:18Z","timestamp":1761078798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913421000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":47,"alternative-id":["S1092913421000903"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151790","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-prolymphocytic leukemia: Is it time to retire this entity?","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2021.151790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151790"}}